Mary Hobart, PhD

  • 5Articles
  • 49.2KReads1
  • 2015–2025Active
  • 20Collaborators
  • 381Citations2

About

Mary Hobart, PhD, is affiliated with Otsuka Pharmaceutical Development & Commercialization Inc. in Princeton, New Jersey. Her publications from 2015 to 2025 focus on clinical research in psychiatry, specifically investigating brexpiprazole as monotherapy and adjunctive treatment for major depressive disorder, posttraumatic stress disorder, and schizophrenia/schizoaffective disorders. Her work includes randomized controlled trials assessing efficacy, safety, and functional outcomes in these conditions.

Publications

JCP
Brexpiprazole in Combination with Sertraline and as Monotherapy in PTSD: A Full-Factorial Randomized Clinical Trial
Original Research

Brexpiprazole in Combination with Sertraline and as Monotherapy in PTSD: A Full-Factorial Randomized Clinical Trial

February 19, 2025

In this 10-week study, brexpiprazole in combination with sertraline, but not as monotherapy, demonstrated the potential to be a new efficacious treatment for PTSD.
, , , et al
JCP
Effects of Brexpiprazole on Functioning in Schizophrenia
Original Research

Effects of Brexpiprazole on Functioning in Schizophrenia

March 1, 2022

Drawing on 4 RCTs and 2 open-label extension studies of brexpiprazole, this analysis looks at the effects of this medication on functioning both in the short term and over...
, , , et al
JCP
Original Research

Efficacy and Safety of Adjunctive Brexpiprazole in MDD

May 22, 2018

Finding effective treatment for depressed patients who do not adequately respond to antidepressant medications is a frequent challenge for clinicians. Read this article to learn about the efficacy, safety,...
, , , et al
JCP
Original Research

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study

September 23, 2015

, , , et al
JCP
Original Research

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants

September 23, 2015

, , , et al

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Ketamine and Psychedelics

Listen to the Podcast
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe